Media Contact:
Lynn Tellefsen
Director of Marketing & Communications
Phone: 212.701.3614
Fax: 212.378.2410
ltellefsen@cahill.com

Legal News

Valeant Pharmaceuticals Completes $365 Million Rule 144A Offering

Date: 06/09/09

Cahill represented UBS Securities LLC and the other initial purchasers in the $365,000,000 Rule 144A Offering by Valeant Pharmaceuticals International of its 8.375% Senior Notes due 2016. The proceeds will be used for general corporate purposes, which may include funding securities repurchases.

Attorney

Media Contact:
Lynn Tellefsen
Director of Marketing & Communications
Phone: 212.701.3614
Fax: 212.378.2410
ltellefsen@cahill.com